Ambush of Clostridium difficile spores by ramoplanin: Activity in an in vitro model

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 5, 2015, Pages 2525-2530

  Kraus, Carl N ^a   Lyerly, Matthew W ^b   Carman, Robert J ^b  

^a NANO ADM Advanced Development and Manufacturing Center   (United States)

^b TECHLAB INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; RAMOPLANIN; VANCOMYCIN; WATER; ANTIINFECTIVE AGENT; DEPSIPEPTIDE;

ARTICLE; BACTERIAL SPORE; BACTERICIDAL ACTIVITY; BACTERIUM ADHERENCE; BACTERIUM DETECTION; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG ACTIVITY; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; RELAPSE; SPORE GERMINATION; TURNOVER TIME; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; DEPSIPEPTIDES; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; SPORES, BACTERIAL; VANCOMYCIN;

EID: 84931275206     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04853-14     Document Type: Article

References (30)

1. Dubberke ER, Olsen MA. 2012. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 55(Suppl):S88-S92. http://dx.doi.org/10.1093/cid/cis335.
2. Lessa FC, Gould CV, McDonald LC. 2012. Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 55(Suppl):S65-S70. http://dx.doi.org/10.1093/cid/cis319.
3. Miller BA, Chen LF, Sexton DJ, Anderson DJ. 2011. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 32:387-390. http://dx.doi.org/10.1086/659156.
4. Figueroa I, Johnson S, Sambol SP, Goldstein EJ, Citron DM, Gerding DN. 2012. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Clin Infect Dis 55(Suppl):S104-S109. http://dx.doi.org/10.1093/cid/cis357.
5. Johnson S, Adelmann A, Clabots CR, Peterson LR, Gerding DN. 1989. Recurrences of Clostridium difficile diarrhea not caused by the original infecting organism. J Infect Dis 159:340-343. http://dx.doi.org/10.1093/infdis/159.2.340.
6. Kamboj M, Khosa P, Kaltsas A, Babady NE, Son C, Sepkowitz KA. 2011. Relapse versus reinfection: surveillance of Clostridium difficile infection. Clin Infect Dis 53:1003-1006. http://dx.doi.org/10.1093/cid/cir643.
7. Marsh JW, Arora R, Schlackman JL, Shutt KA, Curry SR, Harrison LH. 2012. Association of relapse of Clostridium difficile disease with BI/NAP1/027. J Clin Microbiol 50:4078-4082. http://dx.doi.org/10.1128/JCM.02291-12.
8. McFarland LV, Elmer GW, Surawicz CM. 2002. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97:1769-1775. http://dx.doi.org/10.1111/j.1572-0241.2002.05839.x.
9. Walters BA, Roberts R, Stafford R, Seneviratne E. 1983. Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy. Gut 24:206-212. http://dx.doi.org/10.1136/gut.24.3.206.
10. Baines SD, O'Connor R, Saxton K, Freeman J, Wilcox MH. 2009. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 63:520-525. http://dx.doi.org/10.1093/jac/dkn502.
11. Farver DK, Hedge DD, Lee SC. 2005. Ramoplanin: a lipoglycodepsipeptide antibiotic. Ann Pharmacother 39:863-868. http://dx.doi.org/10.1345/aph.1E397.
12. Pelaez T, Alcala L, Alonso R, Martin-Lopez A, Garcia-Arias V, Marin M, Bouza E. 2005. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 49:1157-1159. http://dx.doi.org/10.1128/AAC.49.3.1157-1159.2005.
13. Leach T, Pullman J, Prieto J. 2004. Ramoplanin vs vancomycin in the treatment of Clostridium difficile diarrhea: a phase II study, abstr K-985a. Abstr 44th Intersci Conf Antimicrob Agents Chemother.
14. Freeman J, Baines SD, Jabes D, Wilcox MH. 2005. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 56:717-725. http://dx.doi.org/10.1093/jac/dki321.
15. Wilson KH, Kennedy MJ, Fekety FR. 1982. Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J Clin Microbiol 15:443-446.
16. Bolton RP, Culshaw MA. 1986. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27:1169-1172. http://dx.doi.org/10.1136/gut.27.10.1169.
17. Wong SS, Woo PC, Luk WK, Yuen KY. 1999. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 34:1-6. http://dx.doi.org/10.1016/S0732-8893(98)00139-4.
18. Carman RJ, Simon MA, Petzold HE, III, Wimmer RF, Batra MR, Fernandez AH, Miller MA, Bartholomew M. 2005. Antibiotics in the human food chain: establishing no effect levels of tetracycline, neomycin, and erythromycin using a chemostat model of the human colonic microflora. Regul Toxicol Pharmacol 43:168-180. http://dx.doi.org/10.1016/j.yrtph.2005.06.005.
19. Escobar-Cortes K, Barra-Carrasco J, Paredes-Sabja D. 2013. Proteases and sonication specifically remove the exosporium layer of spores of Clostridium difficile strain 630. J Microbiol Methods 93:25-31. http://dx.doi.org/10.1016/j.mimet.2013.01.016.
20. Chilton CH, Freeman J, Baines SD, Crowther GS, Nicholson S, Wilcox MH. 2013. Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery. J Antimicrob Chemother 68:2078-2082. http://dx.doi.org/10.1093/jac/dkt160.
21. Walker S, Chen L, Hu Y, Rew Y, Shin D, Boger DL. 2005. Chemistry and biology of ramoplanin: a lipoglycodepsipeptide with potent antibiotic activity. Chem Rev 105:449-476. http://dx.doi.org/10.1021/cr030106n.
22. Burns DA, Heap JT, Minton NP. 2010. SleC is essential for germination of Clostridium difficile spores in nutrient-rich medium supplemented with the bile salt taurocholate. J Bacteriol 192:657-664. http://dx.doi.org/10.1128/JB.01209-09.
23. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. 2013. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108:478-498. http://dx.doi.org/10.1038/ajg.2013.4.
24. Akerlund T, Persson I, Unemo M, Noren T, Svenungsson B, Wullt M, Burman LG. 2008. Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. J Clin Microbiol 46:1530-1533. http://dx.doi.org/10.1128/JCM.01964-07.
25. Petrella LA, Sambol SP, Cheknis A, Nagaro K, Kean Y, Sears PS, Babakhani F, Johnson S, Gerding DN. 2012. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain. Clin Infect Dis 55:351-357. http://dx.doi.org/10.1093/cid/cis430.
26. Bagdasarian N, Rao K, Malani PN. 2015. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 313:398-408. http://dx.doi.org/10.1001/jama.2014.17103.
27. Baliban SM, Michael A, Shammassian B, Mudakha S, Khan AS, Cocklin S, Zentner I, Latimer BP, Bouillaut L, Hunter M, Marx P, Sardesai NY, Welles SL, Jacobson JM, Weiner DB, Kutzler MA. 2014. An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo. Infect Immun 82:4080-4091. http://dx.doi.org/10.1128/IAI.01950-14.
28. Karczewski J, Zorman J, Wang S, Miezeiewski M, Xie J, Soring K, Petrescu I, Rogers I, Thiriot DS, Cook JC, Chamberlin M, Xoconostle RF, Nahas DD, Joyce JG, Bodmer JL, Heinrichs JH, Secore S. 2014. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection. Vaccine 32:2812-2818. http://dx.doi.org/10.1016/j.vaccine.2014.02.026.
29. Mathur H, Rea MC, Cotter PD, Ross RP, Hill C. 2014. The potential for emerging therapeutic options for Clostridium difficile infection. Gut Microbes 5:696-710. http://dx.doi.org/10.4161/19490976.2014.983768.
30. Youngster I, Russell GH, Pindar C, Ziv-Baran T, Sauk J, Hohmann EL. 2014. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 312:1772-1778. http://dx.doi.org/10.1001/jama.2014.13875.